ISebe leHlabathi

Ngomhla wama-22 kuJanuwari 2025, "iNature Medicine" yapapasha iziphumo ze-Akeso ngokuzimeleyo yavelisa i-PD-1/CTLA-4 bispecific antibody cadonilimab ngokudibeneyo ne-oxaliplatin kunye ne-capecitabine kunyango lokuqala lwe-inresectable gastric advanced okanye metastatic gastric okanye gastroesophageal j...Funda ngokugqithisileyo»

Ngomhla wesi-8 kweyoMqungu, ngowama-2025, i-National Medical Products Administration (NMPA) yaseTshayina ivumile i-PADCEVTM (enfortumab vedotin) kunye ne-KEYTRUDA (pembrolizumab) kwizigulane zabantu abadala abanomhlaza we-urothelial oqhubele phambili okanye osasazekayo (la/mUC). Imvume ye-NMPA ye-enfortumab vedotin kwi-comb...Funda ngokugqithisileyo»

Ngomhla we-17 kweyoMdumba, ngo-2025, i-Innovent Biologics ibhengeze ukuba iprotheyini yayo yokuqala ye-PD-1/IL-2α-bias bispecific antibody fusion protein, i-IBI363, ifumene i-Fast Track Designation yayo yesibini (FTD) kwi-US Food and Drug Administration (FDA). Olu phawu lusebenza kunyango lwe-nonresistable, ...Funda ngokugqithisileyo»

Ngomhla we-16 kweyoMqungu, ngo-2025, i-IMPACT yabhengeza ukuba iiCapsules zeSenaparib (派舒宁®）zifumene imvume yokuthengisa eTshayina kwiNational Medical Products Administration (NMPA) njengonyango olulodwa lonyango lokugcinwa kwezigulane zabantu abadala abane-epithelial ephucukileyo (FIGO Stages III and IV)...Funda ngokugqithisileyo»

Ngomhla wesi-7 kweyoMdumba, ngowama-2025, iSichuan Kelun-Biotech Biopharmaceutical yabhengeza ukuvunywa kweCetuximab N01 Injection yayo yiNational Medical Products Administration yokunyanga umhlaza we-colorectal osasazekayo (mCRC) eTshayina. Olu vunyiweyo lusekelwe kuphando olukhulu lweklinikhi lwesigaba sesi-3...Funda ngokugqithisileyo»

Ngomhla we-10 kweyoMdumba, ngo-2025, iCARsgen Therapeutics ibhengeza ukuba umntu wokuqala onyangwe ngonyango lwe-allogeneic BCMA CAR-T oluphuhliswe kwiqonga le-THANK-u Plus™, ufumene impendulo epheleleyo (sCR) kunye ne-minimal residual disease (MRD) negativity kuvavanyo lweSuku-28. Yenzelwe ngaphakathi endlwini...Funda ngokugqithisileyo»

Ngomhla wama-29 kweyoMqungu ngo-2025, iqela lophando laseTshayina lapapasha inqaku elinesihloko esithi “I-Neoadjuvant pyrotinib kunye ne-trastuzumab kumhlaza webele one-HER2 positive ngaphandle kwempendulo yangethuba (NeoPaTHer): ukusebenza kakuhle, ukhuseleko, kunye nohlalutyo lwe-biomarker lophando olulungiselelwe impendulo oluneziphumo ezininzi” kwi...Funda ngokugqithisileyo»

Ngomhla wama-26 kweyoMqungu, ngowama-2025, iZiko loVavanyo lwaMayeza (i-CDE) le-China National Medical Products Administration labhengeza ukuba inaliti ye-LM-108 yenzelwe ukubandakanywa kunyango oluphambili lwee-tumor eziqinileyo eziphucukileyo ezine-microsatellite instability (MSI-H) okanye iziphene zokulungisa ukungalingani (dMMR)...Funda ngokugqithisileyo»

Ngomhla wama-20 kweyoMqungu, iNational Medical Products Administration (NMPA) ivumile unyango olutsha lwe-humanized monoclonal antibody tagitanlimab (eyayisakuba yi-KL-A167) lwe-cisplatin kunye ne-gemcitabine kunyango lokuqala lwezigulane ze-recurrent okanye i-metastatic nasopharyngeal carcinoma (NPC). ...Funda ngokugqithisileyo»

Ngomhla we-16 kweyoMqungu, ngowama-2025, i-National Medical Products Administration (NMPA) yaseTshayina ivumile isicelo esitsha se-limertinib (NDA) sokunyanga izigulane zabantu abadala abanomhlaza wemiphunga ongengoweseli encinci (NSCLC) ophucukileyo okanye osasazekayo. Malunga ne-Limertinib Limertinib ...Funda ngokugqithisileyo»

Ngomhla wesi-8 kweyoMqungu, iZiko loVavanyo lwaMayeza (i-CDE) le-National Medical Products Administration (i-NMPA) yaseTshayina linike i-Breakthrough Therapy Designation (BTD) ye-IBI343, i-TOPO1i anti-CLDN18.2 ADC enokuba yeyona ilungileyo kwiklasi, njengonyango olulodwa kunyango lwe-CLDN18.2-positive advanced pancr...Funda ngokugqithisileyo»

Ngomhla wesi-8 kweyoMqungu, ngowama-2025, i-9MW2821 yanikwa iBreakthrough Therapy Designation (BTD) yiZiko loVavanyo lwaMayeza (i-CDE) le-National Medical Products Administration (i-NMPA) eTshayina. I-9MW2821 inikwa kunye ne-toripalimab, i-antibody ye-anti-PD-1 monoclonal, yonyango olungenabungozi, olungachanekanga...Funda ngokugqithisileyo»